Biohaven Pharmaceutical Holding - Stock Price History | BHVN

Historical daily share price chart and data for Biohaven Pharmaceutical Holding since 2021 adjusted for splits. The latest closing stock price for Biohaven Pharmaceutical Holding as of December 03, 2021 is 103.56.
  • The all-time high Biohaven Pharmaceutical Holding stock closing price was 148.48 on November 03, 2021.
  • The Biohaven Pharmaceutical Holding 52-week high stock price is 151.51, which is 46.3% above the current share price.
  • The Biohaven Pharmaceutical Holding 52-week low stock price is 62.57, which is 39.6% below the current share price.
  • The average Biohaven Pharmaceutical Holding stock price for the last 52 weeks is 101.53.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biohaven Pharmaceutical Holding Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 62.4714 53.3800 98.2400 27.5100 85.7100 57.44%
2019 47.8562 36.6900 67.0100 34.5200 54.4400 47.21%
2018 33.6381 28.0900 43.0000 22.4900 36.9800 37.06%
2017 27.4828 17.5000 38.2100 17.5000 26.9800 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.783B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90